CHILDHOOD CANCER SURVIVOR STUDY

儿童癌症幸存者研究

• 批准号: 6375918
• 负责人: LESLIE L ROBISON
• 金额: $ 100.12万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-07-20 至 2005-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6375918
• 关键词: adult human (21+); cancer risk; cooperative study; data collection; family genetics; health behavior; human morbidity; human mortality; human subject; human therapy evaluation; longitudinal human study; neoplasm /cancer relapse /recurrence; neoplasm /cancer therapy; pediatric neoplasm /cancer; quality of life; questionnaires

The resource represented by the Childhood Cancer Survivor Study (CCSS) is the result of a multi-institutional collaborative project, which has established and followed a retrospectively ascertained cohort of over 14,000 five year survivors of childhood cancer diagnosed between 1970 and 1986 and over 6000 sibling controls. Members of the cohort, currently ranging in age from 11 to 48 years (median age 26 years) have provided information encompassing over 200,000 person-years of follow- up since diagnosis of the original cancer. This population represents a large and heterogenous group of childhood cancer survivors treated in a fashion that has direct relevance to most current heterogenous group of childhood cancer survivors treated in a fashion that has direct relevance to most current therapeutic strategies. This characteristic, in combination with the high rate of participation, the extensive characterization of participants' prior therapy, and attention to collection of high quality data, makes the CSS an outstanding and, indeed, unique national resource for the conduct of innovative research. The objectives of this competitive renewal application, which reflects a conversion from a U01 to U24, are to (1) expand the research questions posed in the original grant application by extending the length of follow-up of this unique population with questions posed in the original grant application by extending the length of follow-up of this unique population with approximately 65,000 additional person-years; (b) strengthen the resource by establishing repositories for biological specimens to facilitate future molecular biologic investigations; (c) maintain the current consortium of investigators from specimens to facilitate future molecular biologic investigations; (c) maintain the current consortium of investigations from the 25 participating centers in the United States and Canada, who provide scientific expertise and facilitate ongoing activities; (d) serve as a source of ongoing education for the survivor population; and (3) continue to be a resource for innovative investigator-initiated studies of childhood cancer survivors. These objectives will be achieved through specific aims: (1) continued follow-up and interaction with members of the cohort to educate and ascertain key outcomes; (2) collection and storage of biologic specimens consisting of tumor specimens from subsequent neoplasms, buccal cells as a source of genomic DNA on all members of the cohort, a and peripheral blood for establishment of lymphoblastoid cell lines for survivors who develop a subsequent neoplasm or have a known genetic condition associated with cancer risk; and (3) facilitate the use of the CCSS resource to address important questions related to cancer survivorship including the development and testing of intervention strategies. The CCSS provides a dynamic framework and resource in which to investigate current and future questions regarding consequences of therapy, genetic associations, disease processes and causation, interventions, and quality of life among childhood cancer survivors.

由儿童癌症幸存者研究（CCSS）代表的资源是一个多机构合作项目的结果，该项目已建立并追踪了14,000多名1970年至1986年诊断为诊断的14,000多名儿童癌症的同类，并在1970年至1986年间诊断出了6000多个同胞控制。该队列的成员目前的年龄从11至48岁（中位年龄26岁）不等，自诊断为原始癌症以来，已提供了超过200,000人的随访信息。该人群代表着以一种方式与大多数当前异性疾病的儿童癌症幸存者直接相关的儿童癌症幸存者的大型且异质的群体，该癌症以与大多数当前的治疗策略有关的方式进行治疗。这种特征结合了高度参与率，参与者先前的疗法的广泛特征以及对收集高质量数据的关注，使CSS成为了创新研究的杰出，确实是独特的国家资源。此竞争性更新应用程序的目标反映了从U01到U24的转换，是（1）扩展原始授予应用程序中提出的研究问题，通过扩大此独特人群的随访时间长度，并通过将这一独特人群的随访时间扩大到原始授权应用中提出的问题，并增加了大约65,000个额外的人年； （b）通过建立生物标本存储库来增强资源，以促进未来的分子生物学研究； （c）维持当前从标本的研究者联盟，以促进未来的分子生物学研究； （c）维护美国和加拿大25个参与中心的当前调查财团，他们提供科学专业知识并促进正在进行的活动； （d）为幸存者人口提供持续教育的根源； （3）继续成为创新研究者对儿童癌症幸存者的研究的资源。这些目标将通过特定的目标实现：（1）与队列成员继续进行教育和确定关键结果的持续跟进和互动； （2）收集和存储由随后的肿瘤标本组成的生物标本，随后的肿瘤标本，颊细胞作为同类所有成员的基因组DNA的来源，A和周围血液的基因组DNA来源，用于建立淋巴母细胞系的幸存者，这些生存细胞系的幸存者与随后的肿瘤构成或与属性属性相关的属性属性或与之相关的属性属性。 （3）促进使用CCSS资源来解决与癌症生存有关的重要问题，包括开发和测试干预策略。 CCSS提供了一个动态框架和资源，在其中研究了有关治疗后果，遗传关联，疾病过程和因果关系，干预措施以及生活质量的当前和未来问题。